{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-000432","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2022-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.805874+00:00","generated_at":"2026-06-27T20:38:23.026661+00:00","sec_items":["2.02","8.01","5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spruce Biosciences appoints Javier Szwarcberg as CEO, promotes Samir Gharib to President","bullets":["Javier Szwarcberg, M.D., MPH, appointed CEO and director effective Jan 3, 2022; succeeds interim CEO Michael Grey, who remains Executive Chairman.","Samir Gharib, MBA, promoted to President while continuing as CFO; salary increased to $430,000 with target bonus of 45%.","Szwarcberg receives options to purchase 1,000,000 shares at $4.59; 750k time-vested over 4 yrs, 250k performance-vested on CAHmelia-204 trial milestones.","Preliminary cash, cash equivalents and investments estimated at $121.4M as of Dec 31, 2021 (unaudited)."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-000432","json":"https://secwatch.observer/filing/0001564590-22-000432.json","markdown":"https://secwatch.observer/filing/0001564590-22-000432.md","text":"https://secwatch.observer/filing/0001564590-22-000432.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000156459022000432/0001564590-22-000432-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000156459022000432/sprb-8k_20211229.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:38:23.026661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0bb443267a","claim":"Michael Grey changed role as Interim Chief Executive Officer at SPRUCE BIOSCIENCES, INC..","evidence_excerpt":"Dr. Szwarcberg will succeed Michael Grey, who had served as the Company’s Interim Chief Executive Officer since November 15, 2021, and who will continue to hold his position as Executive Chairman of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000156459022000432/0001564590-22-000432-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"dee069f8dc","claim":"Javier Szwarcberg was appointed as Chief Executive Officer at SPRUCE BIOSCIENCES, INC..","evidence_excerpt":"appointed Javier Szwarcberg, M.D., MPH, as the Company’s Chief Executive Officer, effective January 3, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000156459022000432/0001564590-22-000432-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"f60dddb377","claim":"Javier Szwarcberg was appointed as Class III director at SPRUCE BIOSCIENCES, INC..","evidence_excerpt":"the Board also appointed Dr. Szwarcberg as a member of the Board effective as of the Start Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000156459022000432/0001564590-22-000432-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}